A Phase 1 Multi-Center Trial of Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
Breast - Female | Breast - Male | Breast
What is the purpose of this trial?
The goal in this Phase 1 dose-escalation trial of the anti-IL-6R monoclonal antibody tocilizumab in combination with trastuzumab and pertuzumab in subjects with metastatic HER2 positive breast cancer is to determine the safety, tolerability and recommended Phase 2 dose of tocilizumab given with trastuzumab and pertuzumab every 3 weeks.
- Ages18 years and older
- Trial withUniversity of Michigan
- Start Date07/15/2019
- End Date03/31/2020
- Last Updated10/16/2019
- Study HIC#2000022904